Cediranib Tx in Relapsed Ovarian CA Doesn't Lower Quality of Life

This article originally appeared here.
Share this content:
Cediranib Tx in Relapsed Ovarian CA Doesn't Lower Quality of Life
Cediranib Tx in Relapsed Ovarian CA Doesn't Lower Quality of Life

FRIDAY, March 31, 2017 (HealthDay News) -- Maintenance therapy with cediranib for women with relapsed ovarian cancer is not detrimental to quality of life (QOL), according to a study published online March 24 in Cancer.

Dan P. Stark, M.D., from St James's University Hospital in Leeds, U.K., and colleagues evaluated year-one QOL data among 456 women randomly allocated to receive standard chemotherapy only, chemotherapy with concurrent cediranib, or chemotherapy with cediranib administered concurrently and continued as maintenance as part of the International Collaboration in Ovarian Neoplasm trial for relapsed ovarian cancer.

The researchers found that the rate of questionnaire compliance was similar across the three groups (90 percent at baseline and 76 percent at year one). At one year, the mean global QOL score was lower for the standard chemotherapy group versus the concurrent-maintenance group (P = 0.18). This finding was robust to the effect of missing data, according to sensitivity analyses. Improvement in QOL became statistically significant after adjustments for self-reported diarrhea.

"The maintenance of QOL along with prolonged cancer control suggests that cediranib has a valuable role in the treatment of relapsed ovarian cancer," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures cediranib and partially funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

High Success Rates for Mitral Valve Repair With Robotic Surgery

High Success Rates for Mitral Valve Repair With ...

Minimally invasive surgery linked to fewer discharges to facility, one day less in hospital vs conservative sx

Tattoo-Linked Complications ID'd in Immunosuppressed Female

Tattoo-Linked Complications ID'd in Immunosuppressed Female

Inflammatory myopathy identified in woman with cystic fibrosis on long-term immunosuppressants

Rates of Cardiac Stress Testing Down but Still Higher in CKD

Rates of Cardiac Stress Testing Down but Still ...

Decline in rates of cardiac stress testing in Medicare beneficiaries aged ≥66 years from 2008 to 2012

is free, fast, and customized just for you!




Already a member?

Sign In Now »